(226 days)
Not Found
Not Found
No
The summary describes a manual broth microdilution test for susceptibility testing and inducible clindamycin resistance detection, with no mention of automated analysis or AI/ML technologies.
No.
The device is an in vitro diagnostic product for clinical susceptibility testing, which determines the effectiveness of antibiotics against bacteria rather than directly treating a condition.
Yes.
The document explicitly states multiple times that the product is an "in vitro diagnostic product for clinical susceptibility testing."
No
The device description clearly states it is an "in vitro diagnostic product" and mentions "plates" and "broth test," indicating physical components and chemical reagents, not software alone.
Yes, based on the provided text, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicitly stated in "Intended Use / Indications for Use": The text clearly states, "The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products..." and "...is an in vitro diagnostic product for clinical susceptibility testing."
- Explicitly stated in "Device Description": The text also states, "...is an in vitro diagnostic product for clinical susceptibility testing."
The definition of an In Vitro Diagnostic (IVD) product is one that is used to examine specimens taken from the human body, such as blood, urine, or tissue, to provide information for the diagnosis, prevention, or treatment of disease. The Sensititre plates are used for clinical susceptibility testing of bacteria, which is a key part of diagnosing and guiding treatment for infections.
N/A
Intended Use / Indications for Use
The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species.
Sensititie® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates with Dtest (containing erythromycin at 1 µg/ml and clindamycin at 0.5µg/ml) broth test for Streptococcus pneumoniae and Streptococus spp.-9-Hemolytic Group is an in vitro diagnostic product for clinical susceptibility testing.
The Dtest for broth microdilution test is for manual read detection of inducible clindamycin resistance in Streptococcus pyogenes and Streptococcus agalactiae resistant to erythromycin (MICs ≥ 1 µg/mL) and susceptible or intermediate to clindamycin (MICs ≤ 0.25 µg/mL or 0.5 µg/mL), and to determine absence of inducible clindamycin resistance in Streptococus pneumoniae. The performance of this test for the detection of inducible clindamycin resistance in isolates of S. pneumoniae has not been established.
With S. pyogenes and S. agalactiae, a Dtest (1/0.5 ug/ml) positive (growth) test, determined by manual read, should be reported as inducible clindamycin resistance.
Product codes
JWY, LTT, LTW
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract design of a stylized eagle or bird-like figure, composed of three curved lines that resemble profiles of human faces.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
THERMO FISHER SCIENTIFIC CYNTHIA KNAPP DIRECTOR OF CLINICAL OPERATIONS 1 THERMO FISHER WAY OAKWOOD VILLAGE OH 44146
August 1, 2014
Re: K133847
Trade/Device Name: Sensititre Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates with Dtest (containing erythromycin at 1ug/mL and clindamvcin at 0.5 ug/mL) Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: II Product Code: JWY, LTT, LTW Dated: July 24, 2014 Received: July 25, 2014
Dear Ms. Knapp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the
1
electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Uwe Scherf - S for
Sally Hojvat, M.Sc., PhD. Director Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K133847
Device Name
Sensitite® Haemophilus influenza/Streptococus pneumoniae (HP) MIC Susceptibility plates with Dtest (containing erythromyin at 1 ug/mL and clindamycin at 0.5 ug/mL)
Indications for Use (Describe)
The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species.
Sensititie® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates with Dtest (containing erythromycin at 1 µg/ml and clindamycin at 0.5µg/ml) broth test for Streptococcus pneumoniae and Streptococus spp.-9-Hemolytic Group is an in vitro diagnostic product for clinical susceptibility testing.
The Dtest for broth microdilution test is for manual read detection of inducible clindamycin resistance in Streptococcus pyogenes and Streptococcus agalactiae resistant to erythromycin (MICs ≥ 1 µg/mL) and susceptible or intermediate to clindamycin (MICs ≤ 0.25 µg/mL or 0.5 µg/mL), and to determine absence of inducible clindamycin resistance in Streptococus pneumoniae. The performance of this test for the detection of inducible clindamycin resistance in isolates of S. pneumoniae has not been established.
With S. pyogenes and S. agalactiae, a Dtest (1/0.5 ug/ml) positive (growth) test, determined by manual read, should be reported as inducible clindamycin resistance.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
- Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Druq Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."